• Michael Müller, Johann Volzke, Behnam Subin, Silke Müller, Martina Sombetzki, Emil C Reisinger, and Brigitte Müller-Hilke.
• Core Facility for Cell Sorting and Cell Analysis, Rostock University Medical Center, Rostock, Germany.
• Bmc Med. 2022 Jan 19; 20 (1): 2929.

BackgroundWhile vaccination programs against the severe acute respiratory syndrome virus 2 (SARS-CoV-2) are globally ongoing, disparate strategies for the deployment of spike antigen show varying effectiveness.MethodsIn order to explore this phenomenon, we sought to compare the early immune responses against AZD1222 and BNT162b2. SARS-CoV-2 seronegative participants received a single dose of either vaccine and were analyzed for immune cell, effector T cell, and antibody dynamics.ResultsAZD1222 induced transient leukopenia and major changes among innate and adaptive subpopulations. Both vaccines induced spike protein-specific effector T cells which were dominated by type 1 helper T cell responses following AZD1222 vaccination. A significant reduction of anti-inflammatory T cells upon re-stimulation was also restricted to AZD1222 vaccinees. While IgM and IgG were the dominant isotypes elicited by AZD1222, BNT162b2 led to a significant production of IgG and IgA.ConclusionsOur results suggest that the strategy for spike protein delivery impacts on how and to what extent immune priming against the main SARS-CoV-2 antigen proceeds.© 2022. The Author(s).

16 keywords...

hide…